Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02410525 · ClinicalTrials.gov registry record · Phase 1
A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02410525 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 8 participants.
The verdict
NCT02410525, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
In this study, radioactive PF-06427878 will be administered, through a vein, alone and with 2 different oral doses of non-radioactive PF-06427878 to healthy, adult, male subjects. Positron emission tomography will be used to characterize tissue distribution. The study will also characterize how the study drug behaves in the body, its safety, and how the body tolerates it.
Interventions
- DRUG [11C]PF-06427878
- DRUG PF-06427878 10 mg
- DRUG PF-06427878 600 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-05 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02410525
The ClinicalTrials.gov registry entry for NCT02410525 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which [11C]PF-06427878 is the first listed.
NCT02410525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02410525 about?
NCT02410525 is a clinical study titled "A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning". In this study, radioactive PF-06427878 will be administered, through a vein, alone and with 2 different oral doses of non-radioactive PF-06427878 to healthy, adult, male subjects. Positron emission tomography will be used to characterize tissue distribution. The study will also characterize how the ...
What is the current status of trial NCT02410525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02410525?
The interventions under investigation include: [11C]PF-06427878 (DRUG), PF-06427878 10 mg (DRUG), PF-06427878 600 mg (DRUG).
Who is sponsoring clinical trial NCT02410525?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.